[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 56
1. Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, Monfrecola G: Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol; 2017;10:105-115
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body and presenting with painful nodules, abscesses, sinus tracts, and scarring.
  • Fortunately, a monoclonal antibody against tumor necrosis factor alpha has been recently approved for treatment of moderate to severe HS, offering patients a promising new option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 1994 Jan;53(1):64-6 [8311560.001]
  • [Cites] Ann Intern Med. 2012 Dec 18;157(12):846-55 [23247938.001]
  • [Cites] Am Surg. 2008 Dec;74(12):1177-81 [19097532.001]
  • [Cites] J Invest Dermatol. 2013 Mar;133(3):601-7 [23096707.001]
  • [Cites] Br J Dermatol. 2006 May;154(5):977-8 [16634904.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37692-9 [11477091.001]
  • [Cites] Acta Derm Venereol. 2009 Nov;89(6):595-600 [19997689.001]
  • [Cites] Br J Dermatol. 2012 May;166(5):1023-34 [22136668.001]
  • [Cites] Exp Dermatol. 2013 Mar;22(3):172-7 [23489419.001]
  • [Cites] Dermatol Clin. 2010 Jul;28(3):511-21, 523-4; quiz 522-3 [20510761.001]
  • [Cites] Br J Dermatol. 2011 May;164(5):1017-22 [21250966.001]
  • [Cites] Int J Dermatol. 2010 Aug;49(8):950-5 [21128923.001]
  • [Cites] J Dermatolog Treat. 2012 Aug;23(4):278-83 [22482700.001]
  • [Cites] Cutis. 2002 Apr;69(4):287-8 [12080949.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1261-8 [20184581.001]
  • [Cites] J Dermatolog Treat. 2016;27(3):247-50 [26406923.001]
  • [Cites] Br J Dermatol. 1988 Sep;119(3):345-50 [3179207.001]
  • [Cites] Br J Dermatol. 2010 Jul;163(1):102-6 [20331444.001]
  • [Cites] J Am Acad Dermatol. 2012 Jun;66(6):966-74 [21982063.001]
  • [Cites] Clin Gastroenterol Hepatol. 2016 Jan;14 (1):65-70 [25952308.001]
  • [Cites] J Cutan Med Surg. 2017 Jan/Feb;21(1):48-53 [27432818.001]
  • [Cites] Br J Dermatol. 2013 Jun;168(6):1151-3 [23738637.001]
  • [Cites] Actas Dermosifiliogr. 2014 Sep;105(7):720-2 [24308927.001]
  • [Cites] N Engl J Med. 2016 Aug 4;375(5):422-34 [27518661.001]
  • [Cites] Br J Dermatol. 2015 Aug;173(2):464-70 [25760289.001]
  • [Cites] Clin Gastroenterol Hepatol. 2016 Jan;14 (1):71-9 [25956836.001]
  • [Cites] J Am Acad Dermatol. 1998 Dec;39(6):971-4 [9843011.001]
  • [Cites] J Am Acad Dermatol. 2011 Oct;65(4):790-8 [21641076.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Feb;29(2):371-6 [24909646.001]
  • [Cites] Br J Dermatol. 2008 Sep;159(3):761-3 [18627370.001]
  • [Cites] Dermatology. 2009;219(2):148-54 [19590173.001]
  • [Cites] Arch Dermatol. 1990 Mar;126(3):339-50 [2178558.001]
  • [Cites] South Med J. 1998 Dec;91(12):1107-14 [9853721.001]
  • [Cites] PLoS One. 2012;7(2):e31810 [22359634.001]
  • [Cites] J Med Genet. 1985 Oct;22(5):367-73 [2934550.001]
  • [Cites] J Biol Chem. 2012 Feb 24;287(9):6208-17 [22205705.001]
  • [Cites] Br J Dermatol. 2008 Feb;158(2):370-4 [18047504.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2013 Apr;27(4):473-8 [22339940.001]
  • [Cites] Clin Exp Dermatol. 2007 Mar;32(2):204-5 [17342798.001]
  • [Cites] Dermatology. 2011 Feb;222(1):49-58 [21109728.001]
  • [Cites] Acta Derm Venereol. 2011 May;91(3):328-32 [21394419.001]
  • [Cites] J Am Acad Dermatol. 2014 Apr;70(4):699-703 [24433875.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):721-5 [8977671.001]
  • [Cites] Br J Dermatol. 2016 Jan;174(1):195-7 [25913460.001]
  • [Cites] Eur J Dermatol. 2009 Mar-Apr;19(2):180-1 [19153066.001]
  • [Cites] J Drugs Dermatol. 2009 Feb;8(2):181-3 [19213236.001]
  • [Cites] Australas J Dermatol. 2010 Aug;51(3):186-90 [20695857.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):73-6 [9922015.001]
  • [Cites] Dermatology. 1997;194(4):325-8 [9252751.001]
  • [Cites] J Am Acad Dermatol. 1988 Aug;19(2 Pt 1):355-6 [2971689.001]
  • [Cites] Science. 2010 Nov 19;330(6007):1065 [20929727.001]
  • [Cites] Dermatology. 2007;215(1):41-4 [17587838.001]
  • [Cites] J Am Acad Dermatol. 2008 Oct;59(4):596-601 [18674845.001]
  • [Cites] Acta Derm Venereol. 2014 Nov;94(6):699-702 [24604152.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):731-43 [15525534.001]
  • [Cites] J Am Acad Dermatol. 2014 Dec;71(6):1144-50 [25440440.001]
  • [Cites] J Am Acad Dermatol. 2013 Mar;68(3):412-9 [22921795.001]
  • [Cites] J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):191-4 [8708018.001]
  • [Cites] Exp Dermatol. 2010 Jun;19(6):533-7 [19659829.001]
  • [Cites] Dermatology. 2009;218(2):134-5 [19060466.001]
  • [Cites] Exp Dermatol. 2012 Mar;21(3):176-7 [22379963.001]
  • [Cites] G Ital Dermatol Venereol. 2015 Dec;150(6):731-9 [26513043.001]
  • [Cites] Dermatology. 2011;222(4):342-6 [21757878.001]
  • [Cites] Dermatol Clin. 2016 Jan;34(1):7-16 [26617352.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Sep;23(9):985-98 [19682181.001]
  • [Cites] Clin Exp Immunol. 2014 Sep;177(3):557-70 [24802245.001]
  • [Cites] Br J Dermatol. 2009 Oct;161(4):831-9 [19438453.001]
  • [Cites] Dermatol Online J. 2013 Apr 15;19(4):1 [24021361.001]
  • [Cites] Int J Dermatol. 1983 Jun;22(5):325-8 [6347922.001]
  • [Cites] J Invest Dermatol. 2013 Jan;133(1):97-103 [22931916.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):994-9 [8647993.001]
  • [Cites] APMIS. 1997 May;105(5):378-83 [9201239.001]
  • [Cites] J Rheumatol. 2014 Mar;41(3):490-4 [24429166.001]
  • [Cites] Exp Dermatol. 2012 Oct;21(10):735-9 [22882284.001]
  • [Cites] J Invest Dermatol. 2012 Oct;132(10):2459-61 [22622421.001]
  • [Cites] J Dermatolog Treat. 2006;17(4):211-3 [16971313.001]
  • [Cites] Dermatol Online J. 2014 Mar 17;20(3):null [24656278.001]
  • [Cites] APMIS. 2014 Sep;122(9):804-9 [24475943.001]
  • [Cites] Dermatology. 2009;219(2):143-7 [19590174.001]
  • [Cites] J Am Acad Dermatol. 2009 Apr;60(4):539-61; quiz 562-3 [19293006.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • [Cites] Ann Rheum Dis. 2013 Apr;72(4):626-7 [23148307.001]
  • [Cites] J Am Acad Dermatol. 2007 Apr;56(4):624-8 [17240478.001]
  • [Cites] Actas Dermosifiliogr. 2007 Jun;98(5):325-31 [17555675.001]
  • [Cites] FEMS Immunol Med Microbiol. 2012 Jul;65(2):385-9 [22353357.001]
  • [Cites] Exp Dermatol. 2008 May;17(5):455-6; discussion 457-72 [18400064.001]
  • [Cites] Br J Dermatol. 2011 Jan;164(1):170-5 [20874789.001]
  • [Cites] J Am Acad Dermatol. 2010 Feb;62(2):205-17 [20115947.001]
  • [Cites] ScientificWorldJournal. 2015;2015:479354 [25977937.001]
  • [Cites] Hautarzt. 2001 Oct;52(10 Pt 2):989-92 [11715401.001]
  • [Cites] J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S8-11 [26470623.001]
  • [Cites] Br J Dermatol. 2011 Jul;165(1):194-8 [21428974.001]
  • [Cites] J R Soc Med. 1995 May;88(5):289P-290P [7636825.001]
  • [Cites] Dev Cell. 2005 May;8(5):665-76 [15866158.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Mar;6(3):189-96 [18093218.001]
  • [Cites] Acta Derm Venereol. 2011 Mar;91(2):169-71 [21384087.001]
  • [Cites] Br J Dermatol. 2008 Apr;158(4):691-7 [18241264.001]
  • [Cites] Br J Dermatol. 1990 Jun;122(6):763-9 [2369556.001]
  • [Cites] Clin Exp Dermatol. 1986 Nov;11(6):579-83 [3478160.001]
  • [Cites] J Am Acad Dermatol. 2014 Sep;71(3):460-7 [24880664.001]
  • [Cites] Int J Dermatol. 2010 Dec;49(12):1445-9 [21091684.001]
  • [Cites] Br J Dermatol. 1992 Apr;126(4):415 [1533313.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):211-3 [12890229.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2012 Jul;26(7):911-4 [21605174.001]
  • [Cites] J Am Acad Dermatol. 2017 Jan;76(1):49-53 [27793450.001]
  • [Cites] Arch Dermatol. 2009 May;145(5):580-4 [19451504.001]
  • [Cites] JAMA Dermatol. 2016 Apr;152(4):429-34 [26885728.001]
  • [Cites] Br J Dermatol. 2016 Apr;174(4):839-46 [26641739.001]
  • [Cites] J Antimicrob Chemother. 2016 Feb;71(2):513-20 [26565016.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2014 Oct;28(7):1013-27 [25214437.001]
  • [Cites] Br J Plast Surg. 2003 Jul;56(5):451-61 [12890458.001]
  • [Cites] JAMA Dermatol. 2014 Dec;150(12):1263-4 [25229429.001]
  • [Cites] Clin Exp Dermatol. 2016 Dec;41(8):852-857 [27753139.001]
  • [Cites] Clin Exp Dermatol. 2006 Jan;31(1):154-5 [16309527.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):51-6 [17199566.001]
  • [Cites] Indian Dermatol Online J. 2014 Oct;5(4):491-3 [25396138.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1631-3 [26299257.001]
  • [Cites] JAMA Dermatol. 2014 Dec;150(12):1273-80 [25229996.001]
  • [Cites] Emerg Infect Dis. 2014 Dec;20(12):1990-8 [25418454.001]
  • [Cites] Ann Dermatol. 2012 Nov;24(4):393-7 [23197903.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44 [25640693.001]
  • [Cites] Br J Dermatol. 2012 Feb;166(2):298-305 [22013960.001]
  • [Cites] Arch Dermatol. 2010 Nov;146(11):1265-70 [21079064.001]
  • [Cites] Acta Derm Venereol. 2012 May;92(3):320-1 [22101775.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2014 Jan;28(1):125-6 [23451831.001]
  • [Cites] Acta Derm Venereol. 2013 May;93(3):301-4 [23096596.001]
  • (PMID = 28458570.001).
  • [ISSN] 1178-7015
  • [Journal-full-title] Clinical, cosmetic and investigational dermatology
  • [ISO-abbreviation] Clin Cosmet Investig Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; diagnosis / hidradenitis suppurativa / pathogenesis / treatment
  •  go-up   go-down


2. Chia KM, Liu J, Francis GD, Naderi A: A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia; 2011 Feb;13(2):154-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression of steroid-response genes such as AR and a high rate of ErbB2 amplification.
  • In this study, we have identified a positive feedback loop between the AR and extracellular signal-regulated kinase (ERK) signaling pathways in molecular apocrine breast cancer.
  • In addition, AR inhibition results in the down-regulation of ERK target proteins phospho-RSK1, phospho-Elk-1, and c-Fos using an in vivo molecular apocrine model.
  • In this respect, the inhibition of ERK phosphorylation reduces AR expression and CREB1-mediated transcriptional regulation of AR acts as a downstream connector between the AR and ERK signaling pathways in molecular apocrine cells.
  • Finally, we demonstrate that AR-positive staining is associated with the overexpression of ERK signaling targets phospho-Elk-1 and c-Fos in ER-negative breast tumors, which further supports a cross-regulation between the AR and ERK signaling pathways in molecular apocrine subtype.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Feedback, Physiological. Female. Gene Expression Regulation, Neoplastic. Humans. Mice. Phosphorylation. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Signal Transduction


3. Farkaš R, Ďatková Z, Mentelová L, Löw P, Beňová-Liszeková D, Beňo M, Sass M, Řehulka P, Řehulková H, Raška O, Kováčik L, Šmigová J, Raška I, Mechler BM: Apocrine secretion in Drosophila salivary glands: subcellular origin, dynamics, and identification of secretory proteins. PLoS One; 2014;9(4):e94383
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apocrine secretion in Drosophila salivary glands: subcellular origin, dynamics, and identification of secretory proteins.
  • In contrast to the well defined mechanism of merocrine exocytosis, the mechanism of apocrine secretion, which was first described over 180 years ago, remains relatively uncharacterized.
  • We identified apocrine secretory activity in the late prepupal salivary glands of Drosophila melanogaster just prior to the execution of programmed cell death (PCD).
  • Here we present data showing that the Drosophila salivary glands release all kinds of cellular proteins by an apocrine mechanism including cytoskeletal, cytosolic, mitochondrial, nuclear and nucleolar components.
  • Surprisingly, the apocrine release of these proteins displays a temporal pattern with the sequential release of some proteins (e.g. transcription factor BR-C, tumor suppressor p127, cytoskeletal β-tubulin, non-muscle myosin) earlier than others (e.g. filamentous actin, nuclear lamin, mitochondrial pyruvate dehydrogenase).
  • Although the apocrine release of proteins takes place just prior to the execution of an apoptotic program, the nuclear DNA is never released.
  • Following apocrine secretion, the salivary gland cells remain quite vital, as they retain highly active transcriptional and protein synthetic activity.
  • [MeSH-major] Apocrine Glands / secretion. Drosophila Proteins / secretion. Drosophila melanogaster / metabolism. Salivary Glands / secretion. Salivary Proteins and Peptides / secretion

  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Mol Life Sci. 2009 Sep;66(17):2819-33 [19468686.001]
  • [Cites] Curr Opin Cell Biol. 2009 Aug;21(4):537-42 [19473826.001]
  • [Cites] FEBS Lett. 2009 Sep 3;583(17):2701-9 [19631211.001]
  • [Cites] J Proteome Res. 2009 Nov;8(11):4889-905 [19705875.001]
  • [Cites] FEBS Lett. 2009 Dec 3;583(23):3804-10 [19887068.001]
  • [Cites] J Mass Spectrom. 2010 Jan;45(1):104-11 [19927305.001]
  • [Cites] J Am Acad Dermatol. 2010 Feb;62(2):205-17 [20115947.001]
  • [Cites] J Oral Maxillofac Surg. 2010 Feb;68(2):451-5 [20116722.001]
  • [Cites] Ann Diagn Pathol. 2010 Feb;14(1):1-7 [20123450.001]
  • [Cites] Int J Biochem Cell Biol. 2010 Feb;42(2):181-5 [19944183.001]
  • [Cites] J Cell Biol. 2010 Feb 8;188(3):401-13 [20142423.001]
  • [Cites] J Cell Biol. 2010 Feb 8;188(3):415-28 [20142424.001]
  • [Cites] Ann Anat. 1999 Sep;181(5):437-46 [10560009.001]
  • [Cites] Anat Embryol (Berl). 2000 Jan;201(1):51-61 [10603093.001]
  • [Cites] Cell Death Differ. 2000 Jan;7(1):89-101 [10713724.001]
  • [Cites] J Morphol. 2000 May;244(2):137-42 [10761051.001]
  • [Cites] Annu Rev Biochem. 1999;68:1015-68 [10872471.001]
  • [Cites] Mol Cell. 2000 Mar;5(3):445-55 [10882130.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2000 Sep;238(9):738-45 [11045341.001]
  • [Cites] Biochimie. 2001 Mar-Apr;83(3-4):301-10 [11295490.001]
  • [Cites] Insect Biochem Mol Biol. 2002 Feb;32(2):113-20 [11755052.001]
  • [Cites] J Invest Dermatol. 2003 Feb;120(2):175-81 [12542519.001]
  • [Cites] Histol Histopathol. 2003 Apr;18(2):597-608 [12647810.001]
  • [Cites] Arch Biochem Biophys. 2003 Jul 1;415(1):1-5 [12801506.001]
  • [Cites] Cell Death Differ. 2003 Sep;10(9):940-5 [12934068.001]
  • [Cites] Neuroreport. 2004 Jan 19;15(1):79-81 [15106835.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:170-8 [15153432.001]
  • [Cites] Annu Rev Neurosci. 2004;27:509-47 [15217342.001]
  • [Cites] Cell Mol Life Sci. 2004 Jul;61(13):1546-61 [15224180.001]
  • [Cites] J Electron Microsc (Tokyo). 1966;15(2):94-5 [5965757.001]
  • [Cites] J Electron Microsc (Tokyo). 1964;13(3):139-44 [4862357.001]
  • [Cites] J Electron Microsc (Tokyo). 1968;17(2):158-9 [4177281.001]
  • [Cites] J Biol Chem. 1969 Aug 25;244(16):4406-12 [5806584.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Z Zellforsch Mikrosk Anat. 1972;127(1):50-86 [4336139.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1974;38:655-62 [4208797.001]
  • [Cites] J Invest Dermatol. 1975 Jan;64(1):38-41 [1110304.001]
  • [Cites] J Mol Biol. 1974 Apr 15;84(3):389-98 [4219221.001]
  • [Cites] Eur J Biochem. 1975 Aug 15;56(2):335-41 [1175627.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Nov;72(11):4550-4 [812097.001]
  • [Cites] Dev Biol. 1976 Jan;48(1):191-5 [812742.001]
  • [Cites] Laryngoscope. 1976 Aug;86(8):1164-76 [950858.001]
  • [Cites] Dev Biol. 1976 Dec;54(2):256-63 [825404.001]
  • [Cites] Dev Biol. 1976 Dec;54(2):264-75 [825405.001]
  • [Cites] Dev Biol. 1977 Jul 15;58(2):339-55 [407116.001]
  • [Cites] J Anat. 1978 Oct;127(Pt 2):291-8 [721691.001]
  • [Cites] Anat Rec. 1979 Feb;193(2):269-91 [426299.001]
  • [Cites] Anal Biochem. 1980 Jul 1;105(2):361-3 [6161559.001]
  • [Cites] J Submicrosc Cytol. 1981 Jul;13(3):473-8 [6174736.001]
  • [Cites] Z Mikrosk Anat Forsch. 1982;96(1):130-7 [7102032.001]
  • [Cites] Nucleic Acids Res. 1983 Apr 25;11(8):2411-25 [6304652.001]
  • [Cites] Nature. 1983 Jul 21-27;304(5923):234-41 [6408489.001]
  • [Cites] Int Rev Cytol. 1984;87:253-329 [6370891.001]
  • [Cites] Stain Technol. 1983 Nov;58(6):347-51 [6679126.001]
  • [Cites] Rhinology. 1986 Mar;24(1):57-60 [3704466.001]
  • [Cites] J Electron Microsc Tech. 1989 Feb;11(2):117-25 [2709130.001]
  • [Cites] Chromosoma. 1989 Aug;98(2):81-5 [2476281.001]
  • [Cites] Genes Dev. 1989 Sep;3(9):1288-300 [2558050.001]
  • [Cites] Cell. 1990 Apr 6;61(1):85-99 [2107982.001]
  • [Cites] Histochemistry. 1990;93(5):525-30 [1970553.001]
  • [Cites] Eye (Lond). 2010 Aug;24(8):1396-402 [20150925.001]
  • [Cites] Nature. 2011 Mar 24;471(7339):473-9 [21179090.001]
  • [Cites] Adv Exp Med Biol. 2011;716:107-22 [21713654.001]
  • [Cites] Eur Biophys J. 2011 Sep;40(9):1013-27 [21833780.001]
  • [Cites] Nat Rev Mol Cell Biol. 2011 Sep;12(9):581-93 [21829222.001]
  • [Cites] Exp Dermatol. 2011 Oct;20(10):841-2 [21824197.001]
  • [Cites] Annu Rev Entomol. 2012;57:187-204 [21910636.001]
  • [Cites] Nature. 2012 Oct 11;490(7419):201-7 [23060190.001]
  • [Cites] Physiol Rev. 2012 Oct;92(4):1915-64 [23073634.001]
  • [Cites] Br J Dermatol. 2013 Feb;168(2):243-52 [23106519.001]
  • [Cites] BMC Med. 2013;11:93 [23556533.001]
  • [Cites] Cell Mol Life Sci. 2013 Jun;70(12):2099-121 [22986507.001]
  • [Cites] Genes Dev. 1990 Feb;4(2):204-19 [2110921.001]
  • [Cites] Gene. 1991 Dec 30;109(2):265-7 [1765271.001]
  • [Cites] Acta Anat (Basel). 1992;143(1):7-13 [1350161.001]
  • [Cites] Biotech Histochem. 1993 Jul;68(4):237-9 [8218577.001]
  • [Cites] Microsc Res Tech. 1993 Dec 15;26(6):489-95 [8305726.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1160-73 [7926721.001]
  • [Cites] Eur J Cell Biol. 1994 Oct;65(1):49-59 [7889995.001]
  • [Cites] Biol Reprod. 1995 Jan;52(1):50-62 [7711183.001]
  • [Cites] J Anat. 1994 Aug;185 ( Pt 1):1-49 [7559104.001]
  • [Cites] Anat Embryol (Berl). 1995 Oct;192(4):319-28 [8554165.001]
  • [Cites] Bioessays. 1996 Jan;18(1):47-54 [8593163.001]
  • [Cites] Microsc Res Tech. 1996 Jun 1;34(2):104-10 [8722703.001]
  • [Cites] Cell Tissue Res. 1996 Sep;285(3):501-7 [8772164.001]
  • [Cites] Trends Genet. 1996 Aug;12(8):306-10 [8783940.001]
  • [Cites] Development. 1997 Nov;124(22):4673-83 [9409683.001]
  • [Cites] J Histochem Cytochem. 1998 Apr;46(4):505-11 [9524196.001]
  • [Cites] Anat Rec. 1998 Nov;252(3):403-12 [9811218.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1998 Nov-Dec;34(10):813-23 [9870531.001]
  • [Cites] Cell Tissue Res. 1999 Mar;295(3):495-504 [10022969.001]
  • [Cites] J Invest Dermatol. 1954 Feb;22(2):143-56 [13130897.001]
  • [Cites] J Biophys Biochem Cytol. 1958 Jul 25;4(4):475-8 [13563554.001]
  • [Cites] J Anat. 1959 Apr;93(2):226-32 [13641121.001]
  • [Cites] J Cell Biol. 1963 Apr;17:208-12 [13986422.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Feb;6(2):181-7 [15688003.001]
  • [Cites] Pediatrics. 2005 Feb;115(2):e239-41 [15629957.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Mar;46(3):863-76 [15728542.001]
  • [Cites] Cell Calcium. 2005 Sep-Oct;38(3-4):343-53 [16099500.001]
  • [Cites] Am Fam Physician. 2005 Oct 15;72(8):1547-52 [16273821.001]
  • [Cites] Clin Lab Med. 2005 Dec;25(4):761-75, vii [16308090.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S93-S126 [16446719.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2006 Feb;5(1):57-77 [16613554.001]
  • [Cites] Cell Biochem Biophys. 2006;45(1):111-23 [16679567.001]
  • [Cites] Cell. 2006 Aug 11;126(3):597-609 [16901790.001]
  • [Cites] Cell. 2007 Jan 12;128(1):183-95 [17218264.001]
  • [Cites] Nat Protoc. 2006;1(6):2856-60 [17406544.001]
  • [Cites] J Neurosci. 2007 Apr 18;27(16):4231-2 [17442806.001]
  • [Cites] J Am Acad Nurse Pract. 2007 May;19(5):228-34 [17489955.001]
  • [Cites] Nat Genet. 2007 Jun;39(6):715-20 [17534367.001]
  • [Cites] Ital J Anat Embryol. 2007 Apr-Jun;112(2):117-29 [17687876.001]
  • [Cites] Nat Protoc. 2007;2(8):1896-906 [17703201.001]
  • [Cites] Microsc Res Tech. 2007 Dec;70(12):1022-7 [17661387.001]
  • [Cites] Histopathology. 2008 Jan;52(1):3-10 [18171412.001]
  • [Cites] Nature. 2008 May 22;453(7194):481-8 [18497817.001]
  • [Cites] J Cutan Pathol. 2008 Jul;35(7):701-3 [18582247.001]
  • [Cites] Nat Struct Mol Biol. 2008 Jul;15(7):665-74 [18618940.001]
  • [Cites] Cell Mol Life Sci. 2008 Sep;65(18):2814-32 [18726177.001]
  • [Cites] Am Surg. 2008 Dec;74(12):1177-81 [19097532.001]
  • [Cites] JAAPA. 2008 Nov;21(11):23-5 [19105543.001]
  • [Cites] Science. 2009 Jan 23;323(5913):474-7 [19164740.001]
  • [Cites] Science. 2009 Jan 23;323(5913):516-21 [19164751.001]
  • [Cites] Genetics. 2009 Feb;181(2):543-65 [19064711.001]
  • [Cites] J Cell Biol. 2009 Mar 9;184(5):751-64 [19255244.001]
  • (PMID = 24732043.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Fluorescent Dyes; 0 / Recombinant Fusion Proteins; 0 / Salivary Proteins and Peptides; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC3986406
  •  go-up   go-down


Advertisement
4. Naderi A, Vanneste M: Prolactin-induced protein is required for cell cycle progression in breast cancer. Neoplasia; 2014 Apr;16(4):329-42.e1-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrated that PIP is required for the progression through G1 phase, mitosis, and cytokinesis in luminal A, luminal B, and molecular apocrine breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2014 Neoplasia Press, Inc. Published by Elsevier Inc. All rights reserved.
  • [Cites] Oncogene. 2007 Nov 1;26(50):7163-9 [17525746.001]
  • [Cites] J Cell Biol. 2007 Oct 22;179(2):255-67 [17938250.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3654-62 [19470724.001]
  • [Cites] ACS Chem Biol. 2010 Jan 15;5(1):79-90 [20014865.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1596-610 [19711341.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):488-92 [19887463.001]
  • [Cites] J Cell Sci. 2010 Apr 15;123(Pt 8):1216-26 [20332112.001]
  • [Cites] Cancer Lett. 2010 Dec 1;298(1):74-87 [20605569.001]
  • [Cites] Curr Biol. 2010 Nov 9;20(21):1881-9 [20951045.001]
  • [Cites] Oncogene. 2011 Feb 3;30(5):521-34 [20838383.001]
  • [Cites] J Cell Biol. 2011 Jun 13;193(6):1049-64 [21646403.001]
  • [Cites] J Clin Invest. 2011 Jul;121(7):2750-67 [21633166.001]
  • [Cites] Int J Cancer. 2012 Jan 1;130(1):71-82 [21384344.001]
  • [Cites] Mol Biol Cell. 2011 Nov;22(22):4312-23 [21937723.001]
  • [Cites] J Cell Physiol. 2012 May;227(5):2276-82 [21809344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2724-9 [22003129.001]
  • [Cites] Cancer Res. 2012 Sep 15;72(18):4744-52 [22805305.001]
  • [Cites] Mol Cell Biol. 2013 Jan;33(2):227-36 [23109430.001]
  • [Cites] PLoS Biol. 2013;11(2):e1001495 [23468594.001]
  • [Cites] PLoS One. 2014;8(6):e62361 [23755096.001]
  • [Cites] Adv Cancer Res. 2013;118:97-398 [23768511.001]
  • [Cites] Breast Cancer Res. 2013;15(3):R37 [23663520.001]
  • [Cites] Breast Cancer Res. 2012;14(4):R111 [22817771.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):542-8 [18516291.001]
  • [Cites] Genetics. 2008 Jun;179(2):737-46 [18558649.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):1-13 [19033363.001]
  • [Cites] J Cell Sci. 2009 Apr 15;122(Pt 8):1111-8 [19299461.001]
  • [Cites] J Natl Cancer Inst. 2009 May 20;101(10):736-50 [19436038.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):1002-8 [10576657.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7935-41 [10713110.001]
  • [Cites] Nature. 2000 Sep 7;407(6800):41-7 [10993066.001]
  • [Cites] Curr Biol. 2000 Oct 19;10(20):R760-70 [11069103.001]
  • [Cites] Mol Endocrinol. 2002 Jul;16(7):1696-710 [12089361.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):507-14 [12124798.001]
  • [Cites] Nature. 2002 Sep 5;419(6902):82-6 [12214236.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3311-4 [12429616.001]
  • [Cites] Genes Dev. 2003 Oct 1;17(19):2465-79 [14522949.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):51-6 [15304323.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):970-83 [15249590.001]
  • [Cites] Eur J Biochem. 1991 Mar 28;196(3):743-50 [2013294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):714-8 [8290587.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1680-8 [7509446.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):216-20 [7829219.001]
  • [Cites] Cell Mol Life Sci. 1999 Jan;55(1):108-20 [10065156.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2631-8 [10072505.001]
  • [Cites] Mol Cell. 2004 Nov 5;16(3):387-97 [15525512.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1152-7 [15858577.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3994-4008 [16491124.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Genome Biol. 2006;7(10):R101 [17076897.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1457-63 [17314399.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17):5986-6000 [17591693.001]
  • [Cites] Nat Protoc. 2007;2(8):1896-906 [17703201.001]
  • [Cites] Curr Protoc Cell Biol. 2001 May;Chapter 8:Unit 8.4 [18228389.001]
  • (PMID = 24862759.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA086862; United States / NCI NIH HHS / CA / P30CA086862
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  • [Other-IDs] NLM/ PMC4094838
  •  go-up   go-down


5. Xu D, Bi T, Lan H, Yu W, Wang W, Cao F, Jin K: Syringocystadenoma papilliferum in the right lower abdomen: a case report and review of literature. Onco Targets Ther; 2013;6:233-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syringocystadenoma papilliferum (SCAP) is an uncommon benign adnexal tumor of the skin.
  • It is frequently seen in association with other benign adnexal lesions, such as nevus sebaceous, apocrine nevus, tubular apocrine adenoma, apocrine hidrocystoma, apocrine cystadenoma, and clear cell syringoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23569386.001).
  • [ISSN] 1178-6930
  • [Journal-full-title] OncoTargets and therapy
  • [ISO-abbreviation] Onco Targets Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3615882
  • [Keywords] NOTNLM ; adnexal / benign / skin tumor
  •  go-up   go-down


6. Bedford T, Alperstein A, Nathani Y, Marx R, DeVito P: A rare presentation of triple-negative apocrine breast carcinoma with metastases. J Surg Case Rep; 2014;2014(5)
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare presentation of triple-negative apocrine breast carcinoma with metastases.
  • Apocrine breast carcinoma is a rare subtype of the invasive ductal carcinoma and accounts for as little as 0.3-1% of all breast cancers.
  • Here we present an exceptionally rare case of apocrine breast carcinoma that is a triple receptor negative with metastases and to our knowledge this is the first published case.
  • This is a significant finding because it implies that the tumor would not respond to the typical hormonal agents.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Oxford University Press and JSCR Publishing Ltd. All rights reserved. © The Author 2014.
  • (PMID = 24876514.001).
  • [ISSN] 2042-8812
  • [Journal-full-title] Journal of surgical case reports
  • [ISO-abbreviation] J Surg Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC4021385
  •  go-up   go-down


7. Naderi A, Meyer M: Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer. Breast Cancer Res; 2012 Jul 20;14(4):R111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Molecular apocrine is a subtype of estrogen receptor (ER)-negative breast cancer that is characterized by a steroid-response gene signature.
  • In this study, we investigated the transcriptional regulation of molecular apocrine genes by the AR-ERK feedback loop.
  • METHODS: The transcriptional effects of AR and ERK inhibition on molecular apocrine genes were assessed in cell lines.
  • RESULTS: We found that PIP is the most regulated molecular apocrine gene by the AR-ERK feedback loop and is overexpressed in ER-/AR+ breast tumors.
  • Furthermore, we demonstrated that PIP has a significant functional role in maintaining cell invasion and viability of molecular apocrine cells because of a positive regulatory effect on the Integrin-ERK and Integrin-Akt signaling pathways.
  • In addition, we demonstrated that PIP expression has a profound effect on cell invasion and the viability of molecular apocrine cells.
  • Therefore, PIP signaling may be a potential therapeutic target in molecular apocrine breast cancer.
  • [MeSH-minor] Animals. Antigens, CD29 / metabolism. Apocrine Glands / metabolism. Cell Line, Tumor. Cell Movement / genetics. Cell Survival / genetics. Cluster Analysis. Cyclic AMP Response Element-Binding Protein / metabolism. Disease Models, Animal. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Gene Knockdown Techniques. Humans. Mice. Protein Binding. Protein-Serine-Threonine Kinases / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Androgen / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7935-41 [10713110.001]
  • [Cites] Mod Pathol. 2010 Feb;23(2):205-12 [19898421.001]
  • [Cites] Mol Biol Cell. 2000 Jul;11(7):2485-96 [10888683.001]
  • [Cites] J Cardiovasc Surg (Torino). 2001 Aug;42(4):561-4 [11455297.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609 [11483993.001]
  • [Cites] J Cell Biol. 2001 Nov 12;155(4):505-10 [11696562.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2871-81 [11909979.001]
  • [Cites] Mol Endocrinol. 2002 Jul;16(7):1696-710 [12089361.001]
  • [Cites] Neuron. 2002 Aug 15;35(4):605-23 [12194863.001]
  • [Cites] Arthritis Rheum. 2002 Sep;46(9):2368-76 [12355484.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1704-15 [12657612.001]
  • [Cites] Breast Cancer. 2003;10(3):214-9 [12955033.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] J Biol Chem. 1987 Nov 5;262(31):15236-41 [3667631.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(1):104-8 [2643093.001]
  • [Cites] Mol Cell Endocrinol. 1991 Sep;80(1-3):165-75 [1955075.001]
  • [Cites] Virchows Arch. 1994;425(5):459-65 [7850069.001]
  • [Cites] Science. 1996 Aug 16;273(5277):959-63 [8688081.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):76-85 [9344587.001]
  • [Cites] J Cell Biol. 1998 Apr 6;141(1):241-53 [9531562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12202-7 [9770464.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32377-9 [9829964.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1945-52 [10470139.001]
  • [Cites] Cancer J. 2010 Jan-Feb;16(1):62-5 [20164692.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):488-92 [19887463.001]
  • [Cites] Carcinogenesis. 2010 Apr;31(4):577-86 [20097731.001]
  • [Cites] Mol Cancer. 2010;9:111 [20482821.001]
  • [Cites] Cancer Lett. 2010 Dec 1;298(1):74-87 [20605569.001]
  • [Cites] Breast Cancer Res. 2010;12(4):R63 [20712882.001]
  • [Cites] Neoplasia. 2011 Feb;13(2):154-66 [21403841.001]
  • [Cites] Mod Pathol. 2011 Jul;24(7):924-31 [21552212.001]
  • [Cites] Cancer Cell. 2011 Jul 12;20(1):119-31 [21741601.001]
  • [Cites] J Clin Invest. 2011 Jul;121(7):2750-67 [21633166.001]
  • [Cites] EMBO J. 2011 Aug 3;30(15):3019-27 [21701558.001]
  • [Cites] EMBO J. 2011 Oct 5;30(19):3962-76 [21915096.001]
  • [Cites] EMBO J. 2011 Oct 5;30(19):3885-94 [21934649.001]
  • [Cites] Breast Cancer Res. 2011;13(2):R36 [21457548.001]
  • [Cites] J Cell Physiol. 2012 May;227(5):2276-82 [21809344.001]
  • [Cites] Mol Cell. 2012 Jan 27;45(2):196-209 [22206868.001]
  • [Cites] Oncogene. 2012 Mar 1;31(9):1196-206 [21785460.001]
  • [Cites] Neoplasia. 2012 Apr;14(4):283-96 [22577344.001]
  • [Cites] Oncogene. 2012 Oct 25;31(43):4588-98 [22179832.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jan;7(1):20-31 [16493410.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3994-4008 [16491124.001]
  • [Cites] Bioinformatics. 2006 Sep 15;22(18):2269-75 [16682424.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 30;72(11):1622-31 [16846592.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):684-94 [17234779.001]
  • [Cites] J Biol Chem. 2007 Mar 30;282(13):9482-91 [17277356.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6725-36 [17638883.001]
  • [Cites] Histol Histopathol. 2007 Nov;22(11):1221-30 [17647195.001]
  • [Cites] J Mol Endocrinol. 2007 Aug;39(2):151-62 [17693613.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):542-8 [18516291.001]
  • [Cites] Mol Cancer Res. 2008 Oct;6(10):1544-53 [18922970.001]
  • [Cites] Cell Mol Life Sci. 2009 Feb;66(3):447-59 [18854942.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4649-64 [19567590.001]
  • [Cites] Int J Cancer. 2010 Apr 1;126(7):1596-610 [19711341.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 12):2139-47 [10825287.001]
  • (PMID = 22817771.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / CREB1 protein, human; 0 / Carrier Proteins; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Glycoproteins; 0 / Integrins; 0 / PIP protein, human; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; EC 2.7.1.- / integrin-linked kinase; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ PMC3680918
  •  go-up   go-down


8. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.
  • The anti-tumor effects of nitrosylcobalamin (NO-Cbl), an apoptosis-inducing, vitamin B12-based carrier of nitric oxide (NO), was evaluated in four dogs with spontaneous cancer.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.
  • Tumor regression was measured by physical exam and verified using ultrasound (case 1) and MRI (case 2-4).
  • (1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. (2) The Golden Retriever demonstrated a 53% reduction in tumor volume after 15 months of daily NO-Cbl therapy. (3) The Bichon Frise demonstrated a 43% regression of the primary tumor and a 90% regression of an iliac lymph node measured by MRI after 15 months of treatment.
  • After 61 months, the dog currently has stable disease, normal liver enzymes, CBC analysis, and no evidence of toxicity. (4) The Labrador demonstrated complete regression of the residual tumor after 6 months of treatment.
  • The use of NO-Cbl capitalizes on the tumor-specific properties of the vitamin B12 receptor and represents a promising anti-cancer therapy.
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Dogs. Dose-Response Relationship, Drug. Female. Magnetic Resonance Imaging. Male. Tumor Burden. Ultrasonography

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • [Cites] Eur J Cancer. 2004 Apr;40(6):858-80 [15120042.001]
  • [Cites] J Vet Intern Med. 1988 Jan-Mar;2(1):41-6 [3221354.001]
  • [Cites] Nat Med. 2005 Oct;11(10):1018 [16211022.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):181-93 [15354401.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):19-25 [9527425.001]
  • [Cites] Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):471-4 [11678572.001]
  • [Cites] J Small Anim Pract. 1999 May;40(5):206-10 [10385862.001]
  • [Cites] J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 [16910854.001]
  • [Cites] J Vet Intern Med. 2002 Jan-Feb;16(1):100-4 [11822797.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):75-81 [17591293.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Jul;4(2):112-28 [16102268.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):239-44 [9625434.001]
  • [Cites] J Nucl Med. 1997 May;38(5):717-23 [9170435.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1996 Nov;11(4):225-34 [9020576.001]
  • [Cites] Aust Vet J. 2005 Jun;83(6):340-3 [15986909.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):511-7 [1112759.001]
  • [Cites] Aust Vet J. 2005 Apr;83(4):208-14 [15907038.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 [9507422.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):307-18 [15232130.001]
  • [Cites] J Am Anim Hosp Assoc. 1997 Jul-Aug;33(4):307-12 [9204465.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9 [12096086.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 [7768706.001]
  • [Cites] J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31 [14507100.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Vet Intern Med. 1994 May-Jun;8(3):236-9 [8064663.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jul-Aug;31(4):349-59 [7552669.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):133-43 [8054503.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5588-94 [16847314.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Vet Comp Oncol. 2003 Jun;1(2):94-104 [19379321.001]
  • [Cites] J Neurosurg Anesthesiol. 1994 Apr;6(2):111-5 [8012169.001]
  • [Cites] J Small Anim Pract. 1981 Mar;22(3):119-28 [7230749.001]
  • [Cites] Vet Surg. 2006 Apr;35(3):267-70 [16635006.001]
  • [Cites] Vet Pathol. 1998 May;35(3):223-6 [9598587.001]
  • [Cites] PLoS One. 2007 Dec 12;2(12):e1313 [18074035.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):161-2 [16449674.001]
  • [Cites] J Am Vet Med Assoc. 1987 Sep 15;191(6):720-6 [3679964.001]
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


9. Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, Argani P: Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol; 2011 Apr;135(4):587-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results suggest that luminal cancers demonstrate similar degrees of apocrine differentiation as HER2 cancers.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21411781.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50 CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / PIP protein, human; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ NIHMS666792; NLM/ PMC4352296
  •  go-up   go-down


10. Liu X, Guan Y, Zhang W, Liu S, Liu J, Wang L, Niu Y: Predictors of recurrence in breast cancer subtypes with negative lymph node in a Chinese population. Int J Clin Exp Pathol; 2014;7(6):3202-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis revealed that molecular subtype, expression of VEGF, tumor grade, and vascular invasion were closely correlated with bad outcome.
  • No metastasis was found in patients with pure invasive papillary carcinoma, invasive cribriform carcinoma or adenoid cystic carcinoma, whereas the diagnoses of invasive micropapillary carcinoma, invasive apocrine carcinoma, invasive papillary carcinoma mixed with invasive ductal carcinoma, or metaplastic carcinoma were correlated with distant metastasis and death.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Case-Control Studies. Female. Humans. Ki-67 Antigen / biosynthesis. Middle Aged. Prognosis. Receptor, ErbB-2 / biosynthesis. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Retrospective Studies. Tumor Suppressor Protein p53 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Aug;80(12):1968-73 [10471047.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7350-60 [16145060.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1157-67 [16489069.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1533-9 [16533778.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1644-9 [16873428.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] Breast. 2008 Oct;17(5):484-91 [18508268.001]
  • [Cites] BMC Cancer. 2008;8:307 [18947390.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Apr;135(4):627-36 [18936974.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1153-4 [19204193.001]
  • [Cites] J Natl Cancer Inst. 2009 May 20;101(10):736-50 [19436038.001]
  • [Cites] Nat Rev Cancer. 2009 Oct;9(10):714-23 [19730431.001]
  • [Cites] BMC Cancer. 2009;9:342 [19778431.001]
  • [Cites] J Clin Oncol. 2010 Jun 1;28(16):2784-95 [20404251.001]
  • [Cites] Ann Surg Oncol. 2010 Oct;17 Suppl 3:312-20 [20853052.001]
  • [Cites] Oncologist. 2011;16 Suppl 1:51-60 [21278441.001]
  • [Cites] J Surg Oncol. 2011 Mar 1;103(3):207-11 [21337548.001]
  • [Cites] Ann Acad Med Singapore. 2011 Feb;40(2):90-6 [21468463.001]
  • [Cites] Breast Cancer Res Treat. 2011 Jun;127(3):713-20 [21452022.001]
  • [Cites] Vet J. 2011 Jul;189(1):77-82 [20675158.001]
  • [Cites] Clin Breast Cancer. 2011 Oct;11(5):325-31 [21764391.001]
  • [Cites] Breast Cancer Res Treat. 2011 Nov;130(2):489-98 [21837481.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e151-7 [21420245.001]
  • [Cites] Breast Cancer Res. 2011;13(1):R16 [21291529.001]
  • [Cites] Breast Cancer Res. 2011;13(3):R68 [21699739.001]
  • [Cites] Breast Cancer Res Treat. 2013 Jan;137(1):57-67 [23135572.001]
  • [Cites] J Cancer Res Clin Oncol. 2013 Jan;139(1):77-84 [22932921.001]
  • [Cites] Ann Oncol. 2013 Sep;24(9):2206-23 [23917950.001]
  • [Cites] J Clin Oncol. 2013 Sep 1;31(25):3083-90 [23897954.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):86-96 [14701769.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):857-66 [15198358.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • (PMID = 25031741.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC4097226
  • [Keywords] NOTNLM ; Breast cancer / VEGF / molecular subtype / p53 / recurrence
  •  go-up   go-down






Advertisement